SpliceBio raises $135 million in Series B financing
The round is co-led by EQT Life Sciences and Sanofi Ventures and will advance SB-007 for Stargardt disease and the genetic medicines pipeline.
See the latest news and media coverage for SpliceBio. We track all announcements, press releases, and industry mentions in real time, all in one place.
Genetic medicines biotechnology company developing gene therapies
splice.bioLast updated
In short: SpliceBio began ASTRA dose expansion and raised $135 million in Series B financing.
The round is co-led by EQT Life Sciences and Sanofi Ventures and will advance SB-007 for Stargardt disease and the genetic medicines pipeline.
The Phase 1/2 ASTRA study is set to begin in the first half of 2025. SB-007 is the first Protein Splicing gene therapy to receive IND clearance.
SpliceBio is eligible for up to $216 million in upfront, opt-in and milestone payments plus royalties, with Spark gaining exclusive worldwide rights to its Protein Splicing platform targeting an undisclosed inherited retinal disease.
Co-led by UCB Ventures and Ysios Capital, with NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners; proceeds advance Stargardt disease program to clinic and expand pipeline.
International funds bet on these two Spanish startups. The Swedish fund EQT Ventures and the French Sanofi Ventures co-led the financing round...
SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007, its gene therapy candidate for Stargardt disease....
Three months after dosing the first patient with its dual vector gene therapy, Splicebio SL has closed a $135 million series B to fund the...
SpliceBio, a biotechnology company specialized in gene therapies, closes the largest investment round of a health sector company in Spain. After raising 50...
Track SpliceBio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to SpliceBio and other trending companies.